{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:05:10Z","timestamp":1792202710339,"version":"4.4.0"},"reference-count":105,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>RNA interference is an ancient biological defense mechanism against external invasions. Mechanistically, small interfering RNA (siRNA) can specifically bind to any target gene, according to the principle of complementary base pairing, to exert silencing effects. Therefore, siRNA has the potential to serve as an efficient therapeutic agent for various diseases. However, due to their susceptibility to nucleases, off-target effects, and low cellular uptake, the development of siRNA-based drugs remains challenging. Fortunately, with the advancement in chemical modifications and delivery systems, patisiran, the first siRNA therapeutic, was approved for the treatment of hereditary transthyretin amyloidosis by the United States Food and Drug Administration (FDA) in 2018, which represents a crucial milestone in the field of siRNA research. Subsequently, seven other siRNA drugs were introduced to the market. Thus, siRNA drugs are on their way to becoming standard pharmacotherapy tools. This review presents the mechanisms of action, delivery barriers, chemical modifications, and delivery platforms of siRNA. Furthermore, it also summarizes commercialized siRNA drugs and some clinical trials, thereby providing a comprehensive knowledge map of siRNA drug modifications, delivery strategies, action mechanisms, and updated clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004061","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:00:08Z","timestamp":1777266008000},"page":"1633-1648","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic siRNA: Mechanisms, challenges, strategies, and clinical translation"],"prefix":"10.1097","volume":"139","author":[{"given":"Qiping","family":"Jiang","sequence":"first","affiliation":[{"name":"Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Fu","sequence":"additional","affiliation":[{"name":"Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacong","family":"An","sequence":"additional","affiliation":[{"name":"Biobank of Peking University First Hospital, Peking University First Hospital, Beijing 100032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/pharmaceutics15020320","article-title":"Lipid and peptide-oligonucleotide conjugates for therapeutic purposes: From simple hybrids to complex multifunctional assemblies","volume":"15","author":"F\u00e0brega","year":"2023","journal-title":"Pharmaceutics"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","article-title":"Engineering siRNA therapeutics: Challenges and strategies","volume":"21","author":"Ali Zaidi","year":"2023","journal-title":"J Nanobiotechnology"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s12094-022-03043-y","article-title":"siRNA and targeted delivery systems in breast cancer therapy","volume":"25","author":"Mirzaei","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"27","DOI":"10.17925\/HI.2023.17.1.27","article-title":"Patisiran for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy","volume":"17","author":"Ioannou","year":"2023","journal-title":"Heart Int"},{"key":"R7-20260605","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/35000016","article-title":"Specific interference with gene function by double-stranded RNA in early mouse development","volume":"2","author":"Wianny","year":"2000","journal-title":"Nat Cell Biol"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cmpb.2003.09.002","article-title":"OptiRNAi, an RNAi design tool","volume":"75","author":"Cui","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1535-7163.MCT-06-0195","article-title":"Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo","volume":"6","author":"Mook","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154-155","author":"Yonezawa","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"R11-20260605","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103505","article-title":"Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids","volume":"28","author":"Mendon\u00e7a","year":"2023","journal-title":"Drug Discov Today"},{"key":"R12-20260605","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111985","article-title":"Phase separation of SGS3 drives siRNA body formation and promotes endogenous gene silencing","volume":"42","author":"Tan","year":"2023","journal-title":"Cell Rep"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1093\/nar\/gkad268","article-title":"Impact of stereopure chimeric backbone chemistries on the potency and durability of gene silencing by RNA interference","volume":"51","author":"Liu","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"R14-20260605","first-page":"1","article-title":"RNA interference in mammalian cell systems","volume":"320","author":"Paddison","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"R15-20260605","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.3390\/molecules25112692","article-title":"Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy","volume":"25","author":"Mainini","year":"2020","journal-title":"Molecules"},{"key":"R16-20260605","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/nat.2022.0004","article-title":"Delivery of RNA therapeutics: The great endosomal escape!","volume":"32","author":"Dowdy","year":"2022","journal-title":"Nucleic Acid Ther"},{"key":"R17-20260605","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"RNA"},{"key":"R18-20260605","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.molmed.2006.02.004","article-title":"Innate sensing of self and non-self RNAs by Toll-like receptors","volume":"12","author":"Sioud","year":"2006","journal-title":"Trends Mol Med"},{"key":"R19-20260605","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ijbiomac.2022.07.201","article-title":"Nile tilapia TLR3 recruits MyD88 and TRIF as adaptors and is involved in the NF-\u03baB pathway in the immune response","volume":"218","author":"Gao","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"R20-20260605","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2005.04.010","article-title":"Cell type-specific involvement of RIG-I in antiviral response","volume":"23","author":"Kato","year":"2005","journal-title":"Immunity"},{"key":"R21-20260605","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00430-019-00588-8","article-title":"Innate immune response in patients with acute Zika virus infection","volume":"208","author":"da Silva","year":"2019","journal-title":"Med Microbiol Immunol"},{"key":"R22-20260605","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/cgt.2016.4","article-title":"Precise and efficient siRNA design: A key point in competent gene silencing","volume":"23","author":"Fakhr","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"R23-20260605","doi-asserted-by":"crossref","first-page":"13736","DOI":"10.1021\/acs.jmedchem.2c00873","article-title":"Small interfering RNAs containing dioxane- and morpholino-derived nucleotide analogues show improved off-target profiles and chirality-dependent in vivo knock-down","volume":"65","author":"Hofmeister","year":"2022","journal-title":"J Med Chem"},{"key":"R24-20260605","doi-asserted-by":"crossref","first-page":"14517","DOI":"10.1021\/jacs.2c01679","article-title":"Role of a \u201cMagic\u201d methyl: 2\u2032-Deoxy-2\u2032-\u03b1-F-2\u2032-\u03b2-C-methyl pyrimidine nucleotides modulate RNA interference activity through synergy with 5'-phosphate mimics and mitigation of off-target effects","volume":"144","author":"Guenther","year":"2022","journal-title":"J Am Chem Soc"},{"key":"R25-20260605","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1261\/rna.768207","article-title":"Determinants of targeting by endogenous and exogenous microRNAs and siRNAs","volume":"13","author":"Nielsen","year":"2007","journal-title":"RNA"},{"key":"R26-20260605","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/nprot.2007.278","article-title":"A protocol for designing siRNAs with high functionality and specificity","volume":"2","author":"Birmingham","year":"2007","journal-title":"Nat Protoc"},{"key":"R27-20260605","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0092-8674(03)00759-1","article-title":"Asymmetry in the assembly of the RNAi enzyme complex","volume":"115","author":"Schwarz","year":"2003","journal-title":"Cell"},{"key":"R28-20260605","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nature"},{"key":"R29-20260605","first-page":"434","article-title":"In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs","volume":"7","author":"Borel","year":"2011","journal-title":"J RNAi Gene Silencing"},{"key":"R30-20260605","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.3390\/molecules28062556","article-title":"Novel nanotherapeutics for cancer immunotherapy by PD-L1-aptamer-functionalized and fexofenadine-loaded albumin nanoparticles","volume":"28","author":"Lai","year":"2023","journal-title":"Molecules"},{"key":"R31-20260605","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1007\/s00432-023-04698-y","article-title":"Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine","volume":"149","author":"Yao","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"R32-20260605","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1172\/JCI125228","article-title":"Selective tissue targeting of synthetic nucleic acid drugs","volume":"129","author":"Seth","year":"2019","journal-title":"J Clin Invest"},{"key":"R33-20260605","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat Biotechnol"},{"key":"R34-20260605","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: First global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"R35-20260605","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"R36-20260605","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fphar.2019.00444","article-title":"Current development of siRNA bioconjugates: From research to the clinic","volume":"10","author":"Chernikov","year":"2019","journal-title":"Front Pharmacol"},{"key":"R37-20260605","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1021\/jm050044o","article-title":"Positional effect of chemical modifications on short interference RNA activity in mammalian cells","volume":"48","author":"Prakash","year":"2005","journal-title":"J Med Chem"},{"key":"R38-20260605","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1093\/nar\/gkq341","article-title":"A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects","volume":"38","author":"Bramsen","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"R39-20260605","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2174\/1389450043345083","article-title":"Locked nucleic acids (LNA): Versatile tools for designing oligonucleotide decoys with high stability and affinity","volume":"5","author":"Crinelli","year":"2004","journal-title":"Curr Drug Targets"},{"key":"R40-20260605","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1093\/nar\/gkq568","article-title":"Modulation of thermal stability can enhance the potency of siRNA","volume":"38","author":"Addepalli","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"R41-20260605","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1089\/hum.2022.172","article-title":"Progress in respiratory gene therapy","volume":"33","author":"McLachlan","year":"2022","journal-title":"Hum Gene Ther"},{"key":"R42-20260605","article-title":"Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"R43-20260605","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1090237","article-title":"The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R44-20260605","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121863","article-title":"Polymer-drug conjugates: Design principles, emerging synthetic strategies and clinical overview","volume":"623","author":"Javia","year":"2022","journal-title":"Int J Pharm"},{"key":"R45-20260605","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3390\/molecules22101724","article-title":"Enhancing the therapeutic delivery of oligonucleotides by chemical modification and nanoparticle encapsulation","volume":"22","author":"Sun","year":"2017","journal-title":"Molecules"},{"key":"R46-20260605","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3097","article-title":"Clinical advances of siRNA therapeutics","volume":"21","author":"Hu","year":"2019","journal-title":"J Gene Med"},{"key":"R47-20260605","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Guimar\u00e3es","year":"2021","journal-title":"Int J Pharm"},{"key":"R48-20260605","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J Control Release"},{"key":"R49-20260605","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.3390\/cancers12113130","article-title":"Safety, efficacy and pharcacokinetics of targeted therapy with the liposomal RNA interference therapeutic Atu027 combined with gemcitabine in patients with pancreatic adenocarcinoma. A randomized phase Ib\/IIa study","volume":"12","author":"Schultheis","year":"2020","journal-title":"Cancers"},{"key":"R50-20260605","doi-asserted-by":"crossref","first-page":"18440","DOI":"10.1021\/jp303267y","article-title":"Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core","volume":"116","author":"Leung","year":"2012","journal-title":"J Phys Chem C Nanomater Interfaces"},{"key":"R51-20260605","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"R52-20260605","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119792","article-title":"PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production","volume":"588","author":"Suzuki","year":"2020","journal-title":"Int J Pharm"},{"key":"R53-20260605","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1021\/acsnano.0c10064","article-title":"Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-containing lipid nanoparticles","volume":"15","author":"Sebastiani","year":"2021","journal-title":"ACS Nano"},{"key":"R54-20260605","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41591-022-01679-5","article-title":"Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial","volume":"28","author":"Pajon","year":"2022","journal-title":"Nat Med"},{"key":"R55-20260605","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"R56-20260605","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.121.000805","article-title":"Minimal physiologically based pharmacokinetic-pharmacodynamic (mPBPK-PD) model of N-acetylgalactosamine-conjugated small interfering RNA disposition and gene silencing in preclinical species and humans","volume":"379","author":"Ayyar","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"R57-20260605","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"R58-20260605","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: State of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"R59-20260605","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","article-title":"Mipomersen and its use in familial hypercholesterolemia","volume":"20","author":"Parham","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"R60-20260605","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijpharm.2017.04.008","article-title":"Polymeric nanoparticles for siRNA delivery: Production and applications","volume":"525","author":"Cavallaro","year":"2017","journal-title":"Int J Pharm"},{"key":"R61-20260605","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn7162","article-title":"Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge","volume":"8","author":"Bai","year":"2022","journal-title":"Sci Adv"},{"key":"R62-20260605","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1111\/1759-7714.14618","article-title":"Construction of PEI-EGFR-PD-L1-siRNA dual functional nano-vaccine and therapeutic efficacy evaluation for lung cancer","volume":"13","author":"Yang","year":"2022","journal-title":"Thorac Cancer"},{"key":"R63-20260605","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1021\/acs.jpcb.6b10775","article-title":"Structural comparisons of PEI\/DNA and PEI\/siRNA complexes revealed with molecular dynamics simulations","volume":"121","author":"Ziebarth","year":"2017","journal-title":"J Phys Chem B"},{"key":"R64-20260605","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","article-title":"Strategies, design, and chemistry in siRNA delivery systems","volume":"144","author":"Dong","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"R65-20260605","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"R66-20260605","doi-asserted-by":"crossref","first-page":"80651","DOI":"10.18632\/oncotarget.20869","article-title":"Simultaneous silencing of TGF-\u03b21 and COX-2 reduces human skin hypertrophic scar through activation of fibroblast apoptosis","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"R67-20260605","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/17512433.2019.1567326","article-title":"Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"12","author":"Yang","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R68-20260605","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol Ther"},{"key":"R70-20260605","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000490553","article-title":"Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal: A nationwide study","volume":"51","author":"In\u00eas","year":"2018","journal-title":"Neuroepidemiology"},{"key":"R71-20260605","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.17009","article-title":"Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation","volume":"22","author":"Schmidt","year":"2022","journal-title":"Am J Transplant"},{"key":"R72-20260605","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol"},{"key":"R74-20260605","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2147\/DDDT.S281631","article-title":"Spotlight on givosiran as a treatment option for adults with acute hepatic porphyria: Design, development, and place in therapy","volume":"16","author":"Majeed","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"R75-20260605","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cpt.1802","article-title":"Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria","volume":"108","author":"Agarwal","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"R76-20260605","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N Engl J Med"},{"key":"R78-20260605","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/liv.15090","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study","volume":"42","author":"Ventura","year":"2022","journal-title":"Liver Int"},{"key":"R79-20260605","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.gastro.2022.11.034","article-title":"AGA clinical practice update on diagnosis and management of acute hepatic porphyrias: Expert review","volume":"164","author":"Wang","year":"2023","journal-title":"Gastroenterology"},{"key":"R80-20260605","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: First approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"R81-20260605","first-page":"e69","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"385","author":"Shah","year":"2021","journal-title":"N Engl J Med"},{"key":"R82-20260605","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: Updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"R83-20260605","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"key":"R84-20260605","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ekir.2021.12.001","article-title":"Randomized clinical trial on the long-term efficacy and safety of lumasiran in patients with primary hyperoxaluria type 1","volume":"7","author":"Hulton","year":"2022","journal-title":"Kidney Int Rep"},{"key":"R85-20260605","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.clinthera.2023.06.011","article-title":"Inclisiran for the treatment of hyperlipidemia and for atherosclerotic cardiovascular disease risk reduction: A narrative review","volume":"45","author":"Cowart","year":"2023","journal-title":"Clin Ther"},{"key":"R86-20260605","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/VHRM.S338424","article-title":"Inclisiran: A new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease","volume":"19","author":"Albosta","year":"2023","journal-title":"Vasc Health Risk Manag"},{"key":"R87-20260605","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide therapeutics - A new class of cholesterol-lowering drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N Engl J Med"},{"key":"R88-20260605","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: An analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"R89-20260605","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"R90-20260605","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"R91-20260605","doi-asserted-by":"crossref","DOI":"10.1177\/21501319231172709","article-title":"Implementing an innovative lipid management technique using siRNA LDL-C lowering therapy: Lessons learned in an NHS primary care practice with worked case examples","volume":"14","author":"Deaney","year":"2023","journal-title":"J Prim Care Community Health"},{"key":"R92-20260605","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve in\u00a0vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol Ther"},{"key":"R93-20260605","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R94-20260605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"R95-20260605","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/acsptsci.2c00110","article-title":"Nedosiran, a candidate siRNA drug for the treatment of primary hyperoxaluria: Design, development, and clinical studies","volume":"5","author":"Liu","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"key":"R96-20260605","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: A pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int"},{"key":"R97-20260605","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: First approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"R98-20260605","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort","volume":"19","author":"Pasi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"R99-20260605","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): A multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"R101-20260605","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"R104-20260605","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat Mater"},{"key":"R105-20260605","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169326","article-title":"Statins in high cardiovascular risk patients: Do comorbidities and characteristics matter?","volume":"23","author":"Rossini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R106-20260605","first-page":"14","article-title":"Hyperoxaluria - A major metabolic risk for kidney stone disease","volume":"106","author":"Owino","year":"2013","journal-title":"R I Med J (2013)"},{"key":"R107-20260605","doi-asserted-by":"crossref","first-page":"i9","DOI":"10.1093\/ckj\/sfab232","article-title":"Treatment of primary hyperoxaluria type 1","volume":"15","author":"Gupta","year":"2022","journal-title":"Clin Kidney J"},{"key":"R108-20260605","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1470-2045(21)00091-7","article-title":"Undruggable KRAS-time to rebrand?","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"R109-20260605","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41467-022-35637-z","article-title":"Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis","volume":"14","author":"Han","year":"2023","journal-title":"Nat Commun"},{"key":"R110-20260605","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/svn-2022-002009","article-title":"Penumbra-targeted CircOGDH siRNA-loaded nanoparticles alleviate neuronal apoptosis in focal brain ischaemia","volume":"9","author":"Liu","year":"2024","journal-title":"Stroke Vasc Neurol"},{"key":"R111-20260605","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-23-1456","article-title":"Safety and efficacy of NY-ESO-1 antigen-specific T-cell receptor gene-transduced T lymphocytes in patients with synovial sarcoma: A phase I\/II clinical trial","volume":"29","author":"Kawai","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:05:47Z","timestamp":1786039547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":105,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004061","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"2025-12-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}